News | May 28, 2025
Kerala Ayurveda reports FY25 consolidated revenue higher by 22% at Rs. 137.2 Cr
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
Adjusted EBITDA positive at Rs. 3.1 crore despite investments in marketing, talent hiring and technology over the year
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
Net profit for the?quarter came in at Rs. 2,889.1 crore, up 4.8 per cent from the year earlier, adjusted for exceptional items
Campaign empowers women to prioritise their health through thought provoking films, influencer-led campaigns, scientific and medical podcasts, survivor experiences, and digital awareness
Akums invested Rs. 272 crore in capital expenditure during FY25
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
For the full year FY25, net profit soared 12x to Rs 345 crore
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Subscribe To Our Newsletter & Stay Updated
